Adjuvant capecitabine adds no advantage to bisphosphonate in elderly breast cancer patients

SAN ANTONIO – The combination of capecitabine plus the bisphosphonate ibandronate didn’t improve disease-free survival in elderly women with moderate- or high-risk breast cancers.

After 5 years,...